The promise of cell-based therapies for diabetic complications challenges and solutions

Yagna P R Jarajapu, Maria B. Grant

Research output: Contribution to journalArticle

97 Citations (Scopus)

Abstract

The discovery of endothelial progenitor cells (EPCs) in human peripheral blood advanced the field of cell-based therapeutics for many pathological conditions. Despite the lack of agreement about the existence and characteristics of EPCs, autologous EPC populations represent a novel treatment option for complications requiring therapeutic revascularization and vascular repair. Patients with diabetic complications represent a population of patients that may benefit from cellular therapy yet their broadly dysfunctional cells may limit the feasibility of this approach. Diabetic EPCs have decreased migratory prowess and reduced proliferative capacity and an altered cytokine/growth factor secretory profile that can accelerate deleterious repair mechanisms rather than support proper vascular repair. Furthermore, the diabetic environment poses additional challenges for the autologous transplantation of cells. The present review is focused on correcting diabetic EPC dysfunction and the challenges involved in the application of cell-based therapies for treatment of diabetic vascular complications. In addition, ex vivo and in vivo functional manipulation(s) of EPCs to overcome these hurdles are discussed.

Original languageEnglish (US)
Pages (from-to)854-869
Number of pages16
JournalCirculation Research
Volume106
Issue number5
DOIs
StatePublished - Mar 19 2010
Externally publishedYes

Fingerprint

Diabetes Complications
Cell- and Tissue-Based Therapy
Blood Vessels
Therapeutics
Diabetic Angiopathies
Autologous Transplantation
Population
Endothelial Progenitor Cells
Intercellular Signaling Peptides and Proteins
Cytokines

Keywords

  • Angiogenesis
  • Bone marrow
  • Diabetes
  • Endothelial progenitor cells

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

The promise of cell-based therapies for diabetic complications challenges and solutions. / Jarajapu, Yagna P R; Grant, Maria B.

In: Circulation Research, Vol. 106, No. 5, 19.03.2010, p. 854-869.

Research output: Contribution to journalArticle

Jarajapu, Yagna P R ; Grant, Maria B. / The promise of cell-based therapies for diabetic complications challenges and solutions. In: Circulation Research. 2010 ; Vol. 106, No. 5. pp. 854-869.
@article{c7c5c341a04544d9af9132d1845cf1b2,
title = "The promise of cell-based therapies for diabetic complications challenges and solutions",
abstract = "The discovery of endothelial progenitor cells (EPCs) in human peripheral blood advanced the field of cell-based therapeutics for many pathological conditions. Despite the lack of agreement about the existence and characteristics of EPCs, autologous EPC populations represent a novel treatment option for complications requiring therapeutic revascularization and vascular repair. Patients with diabetic complications represent a population of patients that may benefit from cellular therapy yet their broadly dysfunctional cells may limit the feasibility of this approach. Diabetic EPCs have decreased migratory prowess and reduced proliferative capacity and an altered cytokine/growth factor secretory profile that can accelerate deleterious repair mechanisms rather than support proper vascular repair. Furthermore, the diabetic environment poses additional challenges for the autologous transplantation of cells. The present review is focused on correcting diabetic EPC dysfunction and the challenges involved in the application of cell-based therapies for treatment of diabetic vascular complications. In addition, ex vivo and in vivo functional manipulation(s) of EPCs to overcome these hurdles are discussed.",
keywords = "Angiogenesis, Bone marrow, Diabetes, Endothelial progenitor cells",
author = "Jarajapu, {Yagna P R} and Grant, {Maria B.}",
year = "2010",
month = "3",
day = "19",
doi = "10.1161/CIRCRESAHA.109.213140",
language = "English (US)",
volume = "106",
pages = "854--869",
journal = "Circulation Research",
issn = "0009-7330",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - The promise of cell-based therapies for diabetic complications challenges and solutions

AU - Jarajapu, Yagna P R

AU - Grant, Maria B.

PY - 2010/3/19

Y1 - 2010/3/19

N2 - The discovery of endothelial progenitor cells (EPCs) in human peripheral blood advanced the field of cell-based therapeutics for many pathological conditions. Despite the lack of agreement about the existence and characteristics of EPCs, autologous EPC populations represent a novel treatment option for complications requiring therapeutic revascularization and vascular repair. Patients with diabetic complications represent a population of patients that may benefit from cellular therapy yet their broadly dysfunctional cells may limit the feasibility of this approach. Diabetic EPCs have decreased migratory prowess and reduced proliferative capacity and an altered cytokine/growth factor secretory profile that can accelerate deleterious repair mechanisms rather than support proper vascular repair. Furthermore, the diabetic environment poses additional challenges for the autologous transplantation of cells. The present review is focused on correcting diabetic EPC dysfunction and the challenges involved in the application of cell-based therapies for treatment of diabetic vascular complications. In addition, ex vivo and in vivo functional manipulation(s) of EPCs to overcome these hurdles are discussed.

AB - The discovery of endothelial progenitor cells (EPCs) in human peripheral blood advanced the field of cell-based therapeutics for many pathological conditions. Despite the lack of agreement about the existence and characteristics of EPCs, autologous EPC populations represent a novel treatment option for complications requiring therapeutic revascularization and vascular repair. Patients with diabetic complications represent a population of patients that may benefit from cellular therapy yet their broadly dysfunctional cells may limit the feasibility of this approach. Diabetic EPCs have decreased migratory prowess and reduced proliferative capacity and an altered cytokine/growth factor secretory profile that can accelerate deleterious repair mechanisms rather than support proper vascular repair. Furthermore, the diabetic environment poses additional challenges for the autologous transplantation of cells. The present review is focused on correcting diabetic EPC dysfunction and the challenges involved in the application of cell-based therapies for treatment of diabetic vascular complications. In addition, ex vivo and in vivo functional manipulation(s) of EPCs to overcome these hurdles are discussed.

KW - Angiogenesis

KW - Bone marrow

KW - Diabetes

KW - Endothelial progenitor cells

UR - http://www.scopus.com/inward/record.url?scp=77950883548&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950883548&partnerID=8YFLogxK

U2 - 10.1161/CIRCRESAHA.109.213140

DO - 10.1161/CIRCRESAHA.109.213140

M3 - Article

VL - 106

SP - 854

EP - 869

JO - Circulation Research

JF - Circulation Research

SN - 0009-7330

IS - 5

ER -